Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

V-IMMUNE® for Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
Hol
Brazília2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
31 fő, tervezett
Kezdés
2025. júl. 18.
Várható befejezés
2027. febr. 27.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • 5% (5g/100 ml) intravenous immunoglobin
A regiszteradat frissítve
2026. január 20.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children and adults with immune thrombocytopenia (ITP), a condition where the immune system destroys blood platelets. Their platelet count must be very low.

Életkor
1 year and older
Nem
All sexes can join
A betegség stádiuma
Confirmed ITP that is newly diagnosed, persistent or chronic. No other condition that could cause the low platelet count.
Korábbi kezelés
Cannot join after rituximab within 6 months before Day 1, or any IV immunoglobin within 1 month before Day 1. Cannot join with a planned dose increase of corticosteroids, cyclophosphamide, azathioprine or attenuated androgens before Day 10.
Biomarker vagy leletérték
Platelet count ≤20,000/mm³ at enrollment

A részvétel fő kizáró okai

  • Low platelets not caused by the immune system, or active sepsis
  • Pregnant or breastfeeding
  • Past allergic reaction to blood products, IVIG or IgG, or IgA deficiency
  • Known HIV, HCV or HBV infection
  • Serious heart, liver or kidney problems, past stroke or blood clots, or cancer under active treatment

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥1 year
  • Confirmed diagnosis of immune thrombocytopenia ( newly diagnosed, persistent or chronic)
  • Platelet count ≤20,000/mm³ at the time of enrollment
  • No other conditions that, in the investigator's opinion, could cause thrombocytopenia
  • Agreement to use effective contraceptive practices/methods throughout the entire study participation by female patients of childbearing potential and able to become pregnant, unless there is a documented medical contraindication

Ki nem vehet részt

  • Previous diagnosis of IgA deficiency, history of reactions to products containing IgA, or history of anti-IgA antibodies
  • Participation in any other study involving an investigational product
  • Receipt of rituximab within 6 months prior to Day 1
  • History of hypersensitivity reaction to blood or blood products, IVIG, or any other IgG preparation
  • Known HIV, HCV, or HBV infection
  • History of NYHA class III or IV heart failure
  • Uncontrolled hypertension with systolic BP >180 mmHg or diastolic BP >100 mmHg
  • A history of hyperviscosity states, transient ischemic attack (TIA), stroke, other thromboembolic events, or acute coronary syndrome (ACS)
  • Child-Pugh class B or C liver failure
  • AST (TGO) and/or ALT (TGP) >2.5× the upper limit of normal or 2.5 times baseline values
  • Serum creatinine >2× the upper limit of normal or 2 times baseline values
  • Acute or chronic conditions (e.g., but not limited to, renal disease or diseases predisposing to renal impairment, coronary artery disease, or protein-losing enteropathy) that, in the investigator's opinion, may interfere with the conduct of the study; An acquired health condition such as chronic lymphocytic leukemia, multiple myeloma, or chronic or recurrent neutropenia (absolute neutrophil count <1,000/mm³); History of hemolytic anemia; Receipt of any IV immunoglobin preparation within 1 month prior to Day 1; Use of corticosteroids, cyclophosphamide, azathioprine, or attenuated androgens with a planned dose increase before Day 10 following IV immunoglobin infusion
  • Non-immune thrombocytopenia
  • Active sepsis
  • Pregnancy (pregnant or breastfeeding)
  • Intolerance to any component of V-IMMUNE®
  • BUN >2.5× the upper limit of normal or 2.5 times baseline values
  • Neoplasia under active treatment
  • Alcohol, opioid, or psychotropic substance abuse within the past 12 months

Ez a vizsgálat jelenleg itt érhető el: Brazília.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a multicenter, prospective clinical trial evaluating the efficacy and safety of V-IMMUNE®, a 5% human normal immunoglobulin formulation administered intravenously, for the treatment of immune thrombocytopenia (ITP) in patients aged ≥1 year. The primary objective is to assess the proportion of patients achieving a platelet count ≥50,000/mm³ on or before Day 9 following the first infusion. The trial employs a single-group design, comparing outcomes to historical controls derived from the literature. Eligible patients must have a confirmed diagnosis of ITP with a platelet count ≤20,000/mm³ and no concurrent conditions likely to cause thrombocytopenia. Key exclusions include non-immune thrombocytopenia, active sepsis, pregnancy or lactation, hypersensitivity to blood products or IgG preparations, and various significant comorbidities (e.g., uncontrolled hypertension, severe hepatic or renal impairment, recent rituximab use). The intervention consists of V-IMMUNE® at a dose of 1 g/kg, administered once daily for two consecutive days, with infusion rates titrated from 0.01 mL/kg/min to 0.06 mL/kg/min. Standard pre-medication protocols (IV normal saline and diphenhydramine) are administered to mitigate infusion-related reactions and reduce the risk of thromboembolic events. Patients will be monitored at multiple time points from baseline through Day 90, with primary efficacy evaluation at Day 9. Secondary endpoints include duration of platelet response, overall treatment response rate, bleeding events, and incidence of infusion-related adverse events.

A vizsgálat csoportja

  • Intervention armA vizsgált kezelés

    Intervention arm will receive a human normal immunoglobulin to be administered intravenously, once daily for 2 consecutive days (Day 1 and Day 2). If the platelet count is not maintained for the desired duration after the first immunoglobin infusion, and at the discretion of the investigator and the patient/legal representative, participants may receive up to one additional cycle between Day 15 and Day 30 Pre-Medication Rapid IV infusion of 500 mL of 0.9% saline, 50 mg of diphenhydramine IV followed by saline 0.9% slow infusion Pediatrics, before the infusion of PSI, an IV infusion of 0.9% sodium chloride (normal saline) at 10 mL/kg over 1 hour, up to a maximum volume of 500 mL, will be administered, along with diphenhydramine 1.25 mg/kg IV, up to a maximum dose of 50 mg. At the end of the V IMMUNE® infusion, administer 0.9% sodium chloride IV at 10 mL/kg, up to a maximum of 500 mL, at an infusion rate of 10 mL/kg, to maintain a patent venous access for at least 30 to 40 minutes.

    Kezelés: 5% (5g/100 ml) intravenous immunoglobin

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
V-IMMUNE® for Immune Thrombocytopenia: A Prospective Multicenter Study to Evaluate the Efficacy and Safety of Human Immunoglobulin in Adult and Pediatric Participants With Immune Thrombocytopenia. TIP Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. január 20.